Open Recommendations
Recommendation Number | Significant Recommendation | Recommended Questioned Costs | Recommended Funds for Better Use | Additional Details | |
---|---|---|---|---|---|
D-2021-2126-DEV0PB-0001-0001.a | No | $0 | $0 | ||
(U) Rec. 1.a: The DoD OIG recommended that the Under Secretary of Defense for Acquisition and Sustainment develop and issue implementing guidance for DoD supply chain risk management for DoD materiel in accordance with DoD Instruction 4140.01. | |||||
D-2021-2126-DEV0PB-0001-0002.a | No | $0 | $0 | ||
(U) Rec. 2.a: The DoD OIG recommended that the Director of the Defense Health Agency, after the new DoD implementing guidance for supply chain risk management is published, develop and publish implementing guidance for supply chain risk management specifically for pharmaceuticals, that includes the Component responsible for policy execution. | |||||
D-2021-2126-DEV0PB-0001-0002.b1 | No | $0 | $0 | ||
(U) Rec. 2.b.1: The DoD OIG recommended that the Director of the Defense Health Agency complete the implementation of its Drug Supply Chain Security Act Compliance Strategy by establishing policies and procedures for drugs purchased with Government Purchase Cards or local contracts to comply with the Drug Supply Chain Security Act. | |||||
D-2021-2126-DEV0PB-0001-0002.b2 | No | $0 | $0 | ||
(U) Rec. 2.b.2: The DoD OIG recommended that the Director of the Defense Health Agency complete the implementation of its Drug Supply Chain Security Act Compliance Strategy by, in coordination with the Commander of Defense Logistics Agency Troop Support, establishing policy and procedures for drugs purchased with Defense Logistics Agency-managed processes, including Defense Logistics Agency Depot Stock, Direct Vendor Delivery, and Defense Logistics Agency Electronic Catalog. |